CA-CEPTON-TECHNOLOGIES
23.9.2021 16:02:06 CEST | Business Wire | Press release
Cepton, a Silicon Valley-based innovator of smart lidar solutions has teamed up with Lithuania-based system integrator Belam to improve road user and rail passenger safety by deploying lidar-enabled obstacle detection at railway level crossings. Following the installation of Cepton’s Helius® Smart Lidar System at a busy railway intersection in Europe, the lidar-based solution has monitored over 15,000 train passages with high accuracy to help ensure the safety of pedestrians and other road users. The system has also helped improve the efficiency of the train service and the traffic flow where it is deployed.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210923005369/en/
Belam is a full-service system integrator operating in the Baltics and Northern Europe. Utilizing cutting-edge technologies such as lidar, Belam delivers advanced solutions to transform smart cities by improving the safety and efficiency of transportation infrastructure and railway systems. Through its partnership with Cepton, Belam was able to deliver accurate obstacle detection at a busy rail intersection, with an automated system that minimized unnecessary stops. As a result, the traffic flow at the intersection has become more efficient.
Railway level crossings represent one of the most complex traffic scenarios given the variety of road users such as pedestrians, cyclists, cars and trucks, and the potential risk of collisions with trains. The high speed of passing trains can put road users at risk, thereby requiring accurate real-time monitoring of the traffic at the crossings, even in difficult weather conditions, to make sure that the tracks are free of obstacles when the train is about to approach. This has posed major challenges for some of the existing sensor technologies, such as camera and radar. Radars lack the resolution needed to accurately verify, locate and classify the obstacle. Cameras provide 2D imaging without readily-available information about object size, location and speed, and are susceptible to difficult lighting and weather conditions.
To enable 24/7, accurate obstacle detection, Belam tested a few types of sensors, including lidars and microwave radars through their development process. During an extended testing campaign, Belam concluded that, compared to the other sensors tested, Cepton´s Helius Smart Lidar System provided the most reliable results in terms of eliminating false positives and false negatives. As lidars perform well at night and in various environmental conditions, the Vista®-P90 lidars deployed as part of the Helius system outperformed other technologies tested in generating high-resolution 3D imaging of vehicles, people and other objects, twenty-four hours a day. The ground-breaking Helius perception software processed the lidar data to accurately classify objects and track their speeds and locations in real time. Integrated together with other sensors, including CCTV cameras used for recording license plates during traffic violations, and meteorological sensors used to determine weather conditions, Cepton’s lidar solutions enabled a truly intelligent railway crossing by providing the key information needed to deliver comprehensive traffic analytics and trigger the appropriate responses to help save lives.
As a result, Belam’s system has achieved an accuracy of over 99.9% in obstacle detection. This level of accuracy has enabled the level crossing to achieve a higher safety rating, where passing trains are now allowed to pass at almost twice the speed as they used to. Following implementation of the automated system, stop signs, which were previously installed at this intersection to mandate a full stop for all vehicles before crossing, were removed. This has improved the traffic flow at the crossing and increased the operational efficiency of the train service.
Powered by Cepton’s patented MMT ® (Micro Motion Technology), the Vista-P90 lidar offers a wide field of view coverage (90° horizontal x 40° vertical), along with high resolution and long range at an affordable price point. The sensor is rotation-free, frictionless and mirrorless, making it rugged and capable of continuous, outdoor applications, even in harsh weather conditions. With multi-lidar aggregation, edge computing and a low-bandwidth data output, the Helius smart lidar system is easy to integrate, scale up and maintain.
Belam and Cepton’s partnership opens up new applications for lidar-enabled smart cities . The smart rail crossings can extend into a complete V2X solution, where not only trains, but also cars can use the real-time traffic data at the intersections to avoid potential collisions and optimize travel routes. Road authorities could also benefit from traffic analytics based on the number of vehicles and road users and the directions in which they travel across the intersections to generate models and plans for traffic management.
“Cepton´s high-performance lidar solutions played a key role in helping us address the challenging traffic scenario of busy level crossings. Their lidar sensors particularly impressed us with accurate detection of different objects. The beneficial combination of Cepton’s field-tested sensors and advanced perception software provided reliable and accurate real-time analytics,” said Aleksandras Zidokas, Business Director at Belam.
“Our partnership with Cepton has helped us demonstrate the tremendous potential of lidar technology in smart transportation infrastructure. In addition to making railway intersections safer for road users, our lidar-enabled system also brought about marked improvement in the traffic flow. We look forward to deploying Cepton’s solutions at more locations, as a scaled up network of smart lidars could ultimately enable safer and more efficient transit systems, which will ultimately result in reduced carbon emissions and a greener city.”
Dr. Jun Pei, CEO of Cepton added: “Lidar enables a higher level of safety for everyone on the road, not just drivers, and we built our lidar solutions to achieve that goal. Our partnership with Belam enables the next-generation of rail and road safety applications and extends the capabilities of our high performance lidars and perception solutions into the rail market. We look forward to a deeper collaboration with Belam to make safer rail traffic a reality.”
About Cepton Technologies, Inc.
Cepton provides state-of-the-art, intelligent, lidar-based solutions for a range of markets such as automotive (ADAS/AV), smart cities , smart spaces and smart industrial applications. Cepton’s patented MMT®-based lidar technology enables reliable, scalable and cost-effective solutions that deliver long range, high resolution 3D perception for smart applications.
Founded in 2016 and led by industry veterans with over two decades of collective experience across a wide range of advanced lidar and imaging technologies, Cepton is focused on the mass market commercialization of high performance, high quality lidar solutions. Cepton is headquartered in San Jose, California, USA, with a presence in North America, Germany, Japan, India and China, to serve a fast-growing global customer base. For more information, visit www.cepton.com and follow us on Twitter and LinkedIn .
About Belam
Belam is a company with more than 25 years experience within the Baltic and Nordic market. Today Belam has more than 1000 implemented projects, a developed network of branches both across Lithuania and in other countries. With its experience and a considerable staff, Belam offers its customers the entire scope of services during a project implementation. Professional staff begins its work at the very first stage of the project when the customer is only shaping an idea. The staff helps the customer to transform this idea into a qualitative, secure and effective solution. Owing to financial stability and professionalism of Belam, customers can be sure of the result and the further delivery of qualitative support for the systems built.
Belam is the first integrator company from Baltic countries who was invited to be a member of UNIFE association. Belam are member on UNITEL, and Cybersecurity subgroups.
Belam has on hands experience with different types of sensors and technology’s like Lidar, line scan camera, microwave radar, thermo camera and other.
Belam implemented first in the Baltic states infrastructure for autonomous vehicles V2X in one of high density highway in Lithuania.
For more information, visit: www.belam.eu
View source version on businesswire.com: https://www.businesswire.com/news/home/20210923005369/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release
A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release
Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas
ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 14:30:00 CEST | Press release
OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future
Enhertu® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 14:00:00 CEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority
Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 13:45:00 CEST | Press release
Global teams recognised in the Future Health Challenge for solutions designed to detect health risks earlier and support faster health system decisions Future Health – A Global Initiative by Abu Dhabi and MIT Solve announce the winners of the inaugural Future Health ChallengeWinning solution equips frontline health workers in low-resource settings with mobile clinical decision-support tools, enabling earlier detection and more effective care deliveryTeams competed for a USD 200,000 grand prize and two USD 50,000 runner-up awards on the sidelines of the 79th World Health Assembly in GenevaWinners recognised for solutions advancing anticipatory, data-driven health systems Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, s
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
